Mifepristone tablets
ApprovedTerminated 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Uterine Fibroid
Conditions
Uterine Fibroid
Trial Timeline
Jun 1, 2017 → Jul 12, 2019
NCT ID
NCT03210324About Mifepristone tablets
Mifepristone tablets is a approved stage product being developed by China Resources Pharmaceutical Group for Uterine Fibroid. The current trial status is terminated. This product is registered under clinical trial identifier NCT03210324. Target conditions include Uterine Fibroid.
What happened to similar drugs?
3 of 17 similar drugs in Uterine Fibroid were approved
Approved (3) Terminated (6) Active (8)
Hype Score Breakdown
Clinical
20
Activity
0
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03210324 | Approved | Terminated |
Competing Products
20 competing products in Uterine Fibroid